AstraZeneca

Almac, AstraZeneca Strike CDx Development Pact

Biocartis, AstraZeneca Ink Companion Diagnostic Pact

Grail, AstraZeneca Partner on Companion Dx for Oncology Drugs

FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer

Genomenon, Alexion Pharmaceuticals Team on Rare Disease Dx

Thermo Fisher Scientific, AstraZeneca Team up to Develop CDx for Targeted Drugs

Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer

In Brief This Week: Unilabs, PerkinElmer, Invitae, Becton Dickinson, and More

AmoyDx, AstraZeneca Strike Ovarian Cancer Companion Diagnostic Alliance

Grail Inks Deals With Amgen, AstraZeneca, Bristol Myers Squibb for MRD Test Development

FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Lynparza

Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC

AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials

FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

FDA Approves Lynparza/Avastin With Myriad Genetics CDx for Platinum-Sensitive Ovarian Cancer

Novacyt, AstraZeneca, GSK, University of Cambridge Partner to Increase SARS-CoV-2 Testing in UK

Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic

Myriad Files sPMA With FDA for Test to ID Best Responders to Lynparza, Avastin Combination

Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement